Clinical Trial Update: Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating fruquitinib combined with camrelizumab in refractory colorectal cancer that is non MSI-H/dMMR.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Fruquitinib

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Colorectal Neoplasm | Phase 2 | Status: UNKNOWN